Jivan Sambridhi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 30-12-2024
- Paid Up Capital ₹ 0.40 M
as on 30-12-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 30-12-2024
- Revenue 1266.29%
(FY 2020)
- Profit 89.54%
(FY 2020)
- Ebitda -91.89%
(FY 2020)
- Net Worth 2.06%
(FY 2020)
- Total Assets 47.01%
(FY 2020)
About Jivan Sambridhi Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹1.00 M.
Mohammed Islam, Mohammad Uddin, and Amit Ray serve as directors at the Company.
- CIN/LLPIN
U33110WB2011PTC167834
- Company No.
167834
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jivan Sambridhi Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Islam  | Director | 02-May-2024 | Current |
| Mohammad Uddin | Director | 28-Dec-2018 | Current |
| Amit Ray | Director | 22-Feb-2020 | Current |
Financial Performance of Jivan Sambridhi Pharmaceuticals.
Jivan Sambridhi Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1266.29% increase. The company also saw a substantial improvement in profitability, with a 89.54% increase in profit. The company's net worth moved up by a moderate rise of 2.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jivan Sambridhi Pharmaceuticals?
In 2018, Jivan Sambridhi Pharmaceuticals had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mdfarukuddin Sports Academy Private LimitedActive 3 years 2 monthsMohammed Islam and Mohammad Uddin are mutual person
- Griebs Housing Construction Private LimitedActive 3 years 8 months
Mohammed Islam is a mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Feb 2024 | Others | ₹1.00 M | Open |
How Many Employees Work at Jivan Sambridhi Pharmaceuticals?
Unlock and access historical data on people associated with Jivan Sambridhi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jivan Sambridhi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jivan Sambridhi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
